FibroGen (NASDAQ:FGEN) Now Covered by StockNews.com

StockNews.com started coverage on shares of FibroGen (NASDAQ:FGEN) in a research report sent to investors on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th.

FibroGen Trading Down 15.6 %

FGEN opened at $0.34 on Friday. FibroGen has a twelve month low of $0.18 and a twelve month high of $2.93. The firm has a market cap of $34.47 million, a price-to-earnings ratio of -0.28 and a beta of 0.82. The company has a fifty day simple moving average of $0.36 and a 200 day simple moving average of $0.62.

FibroGen (NASDAQ:FGEN) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.21. The business had revenue of $46.33 million for the quarter, compared to analysts’ expectations of $34.00 million. During the same period in the previous year, the firm posted ($0.52) earnings per share. On average, analysts forecast that FibroGen will post -0.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On FibroGen

A number of institutional investors have recently modified their holdings of FGEN. Cubist Systematic Strategies LLC raised its stake in FibroGen by 3,906.9% during the second quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 280,161 shares in the last quarter. Point72 DIFC Ltd raised its position in shares of FibroGen by 734.2% during the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 45,990 shares in the last quarter. XTX Topco Ltd bought a new position in FibroGen during the second quarter worth $424,000. Acadian Asset Management LLC boosted its holdings in FibroGen by 34.4% in the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock worth $2,997,000 after purchasing an additional 860,854 shares during the period. Finally, Sei Investments Co. increased its stake in FibroGen by 38.4% during the second quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 41,442 shares during the last quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.